Susquehanna International Group, LLP Verona Pharma PLC Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$15.46 - $30.16 $3.33 Million - $6.49 Million	215,100 Added 888.84%	239,300 $6.88 Million
Q2 2024 Aug 15, 2024	SELL	$11.48 - $17.02 $252,560 - $374,440	-22,000 Reduced 47.62%	24,200 $349,000
Q1 2024 May 07, 2024	BUY	$15.3 - $20.24 $1,530 - $2,023	100 Added 0.22%	46,200 $743,000
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $95,520 - $163,760	8,000 Added 21.0%	46,100 $916,000
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $249,390 - $337,977	-15,300 Reduced 28.65%	38,100 $621,000
Q2 2023 Aug 11, 2023	BUY	$19.41 - $23.43 $34,938 - $42,174	1,800 Added 3.49%	53,400 $1.13 Million
Q1 2023 May 16, 2023	SELL	$18.06 - $25.27 $1.94 Million - $2.71 Million	-107,300 Reduced 67.53%	51,600 $1.04 Million
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $1.41 Million - $3.75 Million	-143,400 Reduced 47.44%	158,900 $4.15 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $1.06 Million - $3.48 Million	256,000 Added 552.92%	302,300 $3.09 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $5.06 $164,365 - $234,277	46,300 New	46,300 $194,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.